Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31139953 | 0.91 | MAP4K1 (0.50) | TLK2CRBNLCKTEKHDAC3 | |
| SCHEMBL31139926 | 0.89 | MAP4K1 (0.44) | TLK2LCKTEKMAP4K1KIF11 | |
| SCHEMBL31139940 | 0.85 | TRPV1 (0.46) | TLK2SMYD3LCKTEKMAP4K1 | |
| SCHEMBL31139941 | 0.83 | ROCK2 (0.49) | CRBNSMYD3HDAC3MAP4K1ROCK2 | |
| SCHEMBL31139986 | 0.82 | PLAU (0.53) | TLK2LCKTEKABL1 | |
| SCHEMBL25241592 | 0.81 | MAP4K1 (0.50) | TLK2HDAC3MAP4K1ROCK2 | |
| SCHEMBL30563506 | 0.81 | MAP4K1 (0.50) | TLK2HDAC3MAP4K1ROCK2 | |
| SCHEMBL31139987 | 0.80 | RAB9A (0.56) | LCKTEK | |
| SCHEMBL31139934 | 0.79 | RAB9A (0.55) | — | |
| SCHEMBL5842454 | 0.78 | TLK2 (0.57) | TLK2SMYD3LRRK2HDAC3MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343707-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE | 2024-10-17 | — | — | US | disclosed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343707-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | PRNP, PNP, ZC3HAV1 | TLK2 1711/4885CRBN 2245/4885SMYD3 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.